Pelthos Therapeutics Inc. (PTHS) Operating Margin
- Operating margin · 12 months: Value -133.42%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -133.42% | Operating income / revenue. Period ending 2026-06-30. $-57.78M ÷ $43.30M × 100 ≈ -133.42% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -57.78M USD | Operating Income (Loss) |
| Revenue | 43.30M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 9.27M USD | Cost of Goods and Services Sold |
| Research and development | 1.30M USD | Research and Development Expense |
| Selling, general and administration | 86.87M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-57.78M | $43.30M | $9.27M | $1.30M | $86.87M | -133.42% |
| 2026-03-31 | $-43.68M | $27.70M | $5.66M | $1.22M | $61.92M | -157.70% |
| 2025-12-31 | $-32.43M | $16.80M | $3.99M | $1.23M | $42.45M | -193.09% |
| 2025-09-30 | $-22.25M | (m) | (m) | $1.14M | (m) | (m) |
| 2025-06-30 | $-8.94M | (m) | (m) | $1.41M | (m) | (m) |
| 2025-03-31 | $-7.47M | (m) | (m) | $907.13K | (m) | (m) |
| 2024-12-31 | $-7.57M | (m) | (m) | $1.18M | (m) | (m) |
| 2024-09-30 | $-9.63M | (m) | (m) | $3.19M | (m) | (m) |
| 2024-06-30 | $-8.87M | (m) | (m) | $2.82M | (m) | (m) |
| 2024-03-31 | $-7.88M | (m) | (m) | $2.86M | (m) | (m) |
| 2023-12-31 | $-6.86M | (m) | (m) | $2.58M | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-2.32M | (m) | (m) | $391.73K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |